A systematic review on reporting outcomes and outcome measures in trials on synthetic mesh procedures for pelvic organ prolapse: Urgent action is needed to improve quality of research.


Journal

Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326

Informations de publication

Date de publication:
02 2019
Historique:
received: 27 04 2018
accepted: 24 09 2018
pubmed: 16 11 2018
medline: 6 2 2020
entrez: 16 11 2018
Statut: ppublish

Résumé

The use of synthetic mesh in pelvic organ prolapse surgery is being closely scrutinized because of serious concerns regarding life-changing complications such as erosion, pain, infection, bleeding, dyspareunia, organ perforation, and urinary problems. Randomized trials and their syntheses in meta-analysis offer a unique opportunity to assess efficacy and safety. However, outcomes and outcome measures need to be consistently selected, collected, and reported across randomized trials to be effectively combined in systematic reviews. We evaluated outcome and outcome measure reporting across randomized controlled trials on surgical interventions using synthetic mesh for pelvic organ prolapse. Systematic review of randomized controlled trials using synthetic mesh for the treatment of pelvic organ prolapse. The selected studies were evaluated using Jadad and MOMENT criteria. Outcomes and outcome measures were systematically identified and categorized. Seventy-one randomized trials were included. Twenty-four different types of mesh were identified. Included trials reported 110 different outcomes and 60 outcome measures. Erosion (40 trials, 78%), pain (29 trials, 56%), bleeding (31 trials, 61%), and dyspareunia (25 trials, 49%) were the most frequently reported outcomes. The longest follow up was 74 months. Most randomized trials evaluating surgical interventions using synthetic mesh for pelvic organ prolapse failed to report on clinically important outcomes and to evaluate efficacy and safety over the medium- and long-term. Developing and implementing a minimum data set, known as a core outcome set, in future vaginal prolapse trials could help address these issues.

Identifiants

pubmed: 30431183
doi: 10.1002/nau.23871
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-524

Subventions

Organisme : Department of Health
ID : DRF-2014-07-051
Pays : United Kingdom

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Thais R de Mattos Lourenco (TR)

Department of Obstetrics and Gynaecology, Urogynaecology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Vasilis Pergialiotis (V)

Laboratory of Experimental Surgery and Surgical Research N S Christeas, University of Athens, Medical School, Athens, Greece.

James M N Duffy (JMN)

Balliol College, University of Oxford, Oxford, United Kingdom.
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Constantin Durnea (C)

Department of Obstetrics Gynaecology, Epsom St Helier University Hospitals NHS Trust, London, United Kingdom.

Abdullatif Elfituri (A)

Department of Obstetrics Gynaecology, Epsom St Helier University Hospitals NHS Trust, London, United Kingdom.

Jorge M Haddad (JM)

Department of Obstetrics and Gynaecology, Urogynaecology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Cornelia Betschart (C)

Department of Gynecology, University Hospital of Zurich, Zurich, Switzerland.

Gabriele Falconi (G)

Department of Obstetrics and Gynaecology, San Bortolo Hospital, Vicenza, Italy.

Stergios K Doumouchtsis (SK)

Laboratory of Experimental Surgery and Surgical Research N S Christeas, University of Athens, Medical School, Athens, Greece.
Department of Obstetrics Gynaecology, Epsom St Helier University Hospitals NHS Trust, London, United Kingdom.
St George's University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH